Latest news with #BonNaturalLifeLimited
Yahoo
22-05-2025
- Business
- Yahoo
BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade
XI'AN, China, May 22, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a leading functional ingredient distributor in China. The term of the Agreement is 24 months with a total contract value of US$ 24 million. Pursuant to the agreement, Shanghai Risesun will market, distribute and sell BON's tea pigment series health products in China. Leveraging a robust biological profile that includes lipid modulation, glycemic control, antioxidant activity, and anti-peptic ulcer, tea pigments demonstrate broad applicability across multiple health sectors. This phytochemical complex now stands as one of the more promising functional tea derivatives since the commercialization of tea polyphenols, gaining particular traction in two high-demand sectors: digestive wellness and blood glucose regulation. Backed by an ample supply of tea raw materials and supported by tea's global popularity as one of the largest beverage categories, this innovation is well-positioned for mass adoption. With robust consumer interest and strong market fundamentals, the venture could potentially exceed a $1 billion market valuation. Hu Yongwei, CEO and Chairman of BON, commented: 'This strategic collaboration with Shanghai Risesun capitalizes on core tea pigment technologies to help accelerate our entry into the high-growth digestive health sector. This transformative partnership marks a strategic milestone in advancing our health solutions business while expanding global commercialization of tea pigment-based products-positioning BON as a leader in this category. We anticipate this alliance will fuel revenue and earnings growth, and potentially elevate shareholder returns through sustainable market expansion.' About Bon Natural Life Limited ('BON') BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at For more information, please contact: Cindy Liu | IREmail: bonnatural@ Safe Harbor Statement This press release contains certain statements that may include 'forward-looking statements.' All statements other than statements of historical fact included herein are 'forward-looking statements.' These forward-looking statements are often identified by the use of forward-looking terminology such as 'believes', 'expects' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split
XI'AN, China, May 15, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that it will effect a 1-for-25 reverse stock split ("Reverse Stock Split") of its authorized, issued and outstanding Class A ordinary shares, par value $0.001 per share. The Reverse Stock Split will become effective at 12:01a.m., Eastern Time, on May 19, 2025. At such time, each 25 issued and outstanding Class A ordinary shares will automatically be reclassified into one new Class A ordinary share. Proportional adjustments will be made to outstanding equity awards, warrants and convertible notes, and to the number of shares issued and issuable under the Company's stock incentive plans and certain existing agreements. No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up. The Reverse Stock Split will affect all Class A holders uniformly and will not alter any stockholder's percentage interest in the Company's equity. Bon's Class A ordinary shares will continue to trade on The Nasdaq Capital Market under the existing symbol "BON" and will begin trading on a split-adjusted basis when the market opens on May 19, 2025. The new CUSIP number for the Class A ordinary shares following the Reverse Stock Split will be G14492204. The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement in order to maintain its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement. Immediately following the Reverse Split our authorized share capital will increase to 1,000,000,000 Class A ordinary shares, par value $0.025 per share; (ii) 50,000,000 Class B ordinary shares, par value $0.001 per share; and (iii) 50,000,000 preference shares, par value $0.001 per share. In addition to the Reverse Split and increase in authorized shares, the conversion rate of the Class B ordinary shares, which are currently convertible to Class A ordinary shares on a one-to-one (1:1) basis, will be convertible to Class A ordinary shares on a one-to-twenty-five (1:25) basis (the 'Variation of Class Rights'). The Reverse Split, Variation of Class Rights, and increase in authorized shares was approved by our shareholders at their April 15, 2025 extraordinary general meeting and was accomplished by way of an amendment to our charter documents filed on April 28, 2025. About Bon Natural Life Limited BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit Forward-Looking Statements Certain statements in this announcement are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission. Investor Relations Contact: Cindy Liu | IR Email: bonnatural@ in to access your portfolio
Yahoo
02-05-2025
- Business
- Yahoo
Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications
XI'AN, China, May 02, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that on April 29, 2025, the Company received a letter (the 'Notification Letter') from the Listing Qualifications Staff (the 'Staff') of The Nasdaq Stock Market, LLC ('Nasdaq'), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the 'Minimum Bid Price Requirement'), as the Company's closing bid price for its Class A ordinary shares, par value US$0.001 per share was below $1.00 per share for the prior thirty (30) consecutive business days, which matter serves as a basis for delisting the Company's securities from Nasdaq. Additionally, the Company's securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii). This serves as an additional basis for delisting, and as such, the Company is not eligible for a compliance period. On May 1, 2025, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company's securities pursuant to their discretionary authority under Listing Rule 5101. The Staff's determination was based on public interest concerns in relation to the Company's March 2025 best efforts offering. The Company has filed a notice of appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff's determination. The appeal will stay delisting of the Company's securities pending the Panel's decision. The Company will evaluate available options to regain compliance with the aforementioned Listing Rules. However, there are no assurances that the Company will be able to regain or maintain compliance or that any such appeal to the Panel will be successful, as applicable. About Bon Natural Life Limited BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit Forward-Looking Statements Certain statements in this announcement are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission. Investor Relations Contact: Cindy Liu | IR Email: bonnatural@ in to access your portfolio
Yahoo
11-04-2025
- Business
- Yahoo
BON Announces Apple Polyphenol Commercial Order Signed
XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply agreement worth $12M with Shanghai Yunsheng, China's premier functional ingredients distributor, to co-develop next-generation apple polyphenol-infused health solutions. The partnership leverages BON's patented extraction technology to deliver science-backed formulations combining antioxidant-rich apple polyphenols with plant-based proteins, proven to support weight management and metabolic health. Protein supplements have evolved into a mainstream wellness staple over decades, cementing their role in fitness regimens, immune health protocols, and longevity-focused nutrition. The strategic incorporation of apple polyphenols into these formulations now unlocks targeted benefits-clinically validated lipid management, enhanced body composition outcomes, and mitigation of age-related muscle atrophy-positioning this innovation at the convergence of proven demand and novel functionality. Early market validation proves compelling-comparable apple polyphenol blends have achieved blockbuster status since launch, selling over half a million units monthly and generating $40M in recurring revenue. Industry analysts note this reflects growing consumer willingness to pay premium pricing for validated "nutraceutical crossover" products. 'As one of the world's premier apple polyphenol suppliers, we're leveraging our vertically integrated supply chain to dominate this high-growth niche,' said Yongwei Hu, Chairman and CEO of the Company, 'the company anticipates compounding revenue streams from the ingredient's dual applications-both as a standalone nutraceutical and as a functional food additive-while maintaining disciplined margin control to maximize shareholder returns.' About Bon Natural Life Limited ("BON") BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at For more information, please contact: Cindy Liu | IR Email: bonnatural@ Safe Harbor Statement This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking in to access your portfolio
Associated Press
25-03-2025
- Business
- Associated Press
BON Announces Revolutionary Postbiotic Blood Sugar Solution Nears Patent Launch
Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced on Thursday, March 20 that a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar was gearing up for release. Yongwei Hu, CEO & Chairman of BON, said 'Backed by a robust IP strategy, BON is aggressively pursuing global patent protection. Over the next two years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal.' As China pushes its Healthy China 2030 agenda, the health industry is riding a sustained growth wave. According to iiMedia Data, a local authoritative third-party data monitoring institution, the market size of China's health food products industry in 2023 exceeded 328 billion RMB ($45.5 billion), and is expected to reach 423.7 billion RMB ($58.8 billion) by 2027. Among them, vitamins and dietary supplements (VDS) account for over half of the total market. While China's VDS spending per capita remains 22% of the U.S. levels, analysts project accelerated demand driven by aging demographics and preventive healthcare trends. BON is positioning itself at the forefront of this fastest-growing industry. A strategic partnership built on March 9 with China's agricultural giant Sanzhuliang Group Co., Ltd. signals BON's ambition to bridge farming and biotech. The collaboration, facilitated by the Listed Companies Division of Commercial Culture Association of China, will focus on biotech innovation, functional food R&D, smart agriculture, industry standards, and more. An expert workstation under the Division was launched at BON's headquarters to advance digital transformation and promote traditional Chinese medicine globally. The Company's recent stock surge underscores investor confidence in its leadership in China's trillion-dollar functional food market. On Friday, March 14, BON stock skyrocketed over 300%, triggering multiple trading halts. Days later, BON priced a best efforts offering of $12 million, before deducting placement agent fees and other estimated expenses payable by the Company. BON intends to use the net proceeds from this offering for R&D, product expansion, global marketing and other corporate purposes. As one of the few suppliers of stachyose, an extract from stachy affinis and also a prebiotic that can promote human intestinal health, BON has built an international footprint with products sold across Asia, the U.S., and the EU. Its portfolio includes stachyose, apple polyphenols, broccoli extracts, and proprietary formulations like probiotic powder drinks and micro-eco repair shampoos. About Bon Natural Life Limited ('BON') Country: China
